hit counter
Aquestive Therapeutics, Inc. (AQST) Stock News Sentiment & Price - Sentifly
AQST - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aquestive Therapeutics, Inc. (AQST)

USA
Biotechnology
NASDAQ
AQST Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AQST Latest news
Seeking Alpha
Neutral
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript
2021-11-03 16:44

Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
2021-11-02 19:54

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance
2021-11-02 16:30

WARREN, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent developments in its business.

Zacks Investment Research
Negative
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2021-10-26 16:41

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
2021-10-25 08:31

WARREN, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced positive topline data from its first-in-human Phase 1 PK study of AQST-109 sublingual film for the delivery of epinephrine in the emergency treatment of allergic reactions including anaphylaxis. Findings from this study support AQST-109's potential as the first orally administered epinephrine treatment for anaphylaxis, with safety, tolerability, PK and pharmacodynamics (PD) measures that fall within the target range of standard of care autoinjectors such as epinephrine pens which require patients or caregivers to inject into their thighs during an emergency allergic reaction.

GlobeNewsWire
Neutral
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
2021-10-14 08:00

WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will report results for third quarter ended September 30, 2021 and provide an update on recent developments in its business after market close on Tuesday, November 2, 2021.

GlobeNewsWire
Neutral
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement
2021-10-06 17:59

WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders providing for a bridge waiver of the first principal payment due under its 12.5% Senior Secured Notes (the “Notes”) in order to provide sufficient time for the parties to execute a definitive agreement to extend the time when the first principal payment is due under the Notes to March 30, 2023.

GlobeNewsWire
Neutral
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
2021-08-06 08:00

WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in a panel entitled “Got My Mind Set On You - Advancing Novel Epilepsy Targets” at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference to be held on Wednesday, August 11, 2021 at 11:30 am ET. The team will also host one-on-one investor meetings throughout the conference.

Seeking Alpha
Neutral
Aquestive Therapeutics' (AQST) CEO Keith Kendall on Q2 2021 Results - Earnings Call Transcript
2021-08-04 11:34

Aquestive Therapeutics' (AQST) CEO Keith Kendall on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
2021-08-03 20:35

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Loading more news...